These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8906230)

  • 21. Structure/function analysis of human interleukin 5 and its receptor.
    Tavernier J; Cornelis S; Devos R; Guisez Y; Plaetinck G; Van der Heyden J
    Agents Actions Suppl; 1995; 46():23-34. PubMed ID: 7610988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutagenesis in the C-terminal region of human interleukin 5 reveals a central patch for receptor alpha chain recognition.
    Morton T; Li J; Cook R; Chaiken I
    Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10879-83. PubMed ID: 7479902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A potent dimeric peptide antagonist of interleukin-5 that binds two interleukin-5 receptor alpha chains.
    England BP; Balasubramanian P; Uings I; Bethell S; Chen MJ; Schatz PJ; Yin Q; Chen YF; Whitehorn EA; Tsavaler A; Martens CL; Barrett RW; McKinnon M
    Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6862-7. PubMed ID: 10823900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-5.
    McKenzie AN; Sanderson CJ
    Chem Immunol; 1992; 51():135-52. PubMed ID: 1567540
    [No Abstract]   [Full Text] [Related]  

  • 25. Monomeric isomers of human interleukin 5 show that 1:1 receptor recruitment is sufficient for function.
    Li J; Cook R; Doyle ML; Hensley P; McNulty DE; Chaiken I
    Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6694-9. PubMed ID: 9192627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Interleukin 5 and allergy].
    Takatsu K
    Arerugi; 1994 Oct; 43(10):1229-39. PubMed ID: 7826218
    [No Abstract]   [Full Text] [Related]  

  • 27. Functional analysis of the interleukin-5 receptor antagonist peptide, AF18748.
    Rosas M; Uings IJ; van Aalst C; Lammers JW; Koenderman L; Coffer PJ
    Cytokine; 2004 Jun; 26(6):247-54. PubMed ID: 15183842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modified peptide antagonists of interleukin 5 exhibit extended in vivo persistence but restricted species specificity.
    Uings IJ; Balasubramanian P; McLoughlin PG; Yin Q; Dash L; Beresford A; Kearney S; Barrett RW; McKinnon M; England BP
    Cytokine; 2001 Jul; 15(1):10-9. PubMed ID: 11509004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multisite mutagenesis of interleukin 5 differentiates sites for receptor recognition and receptor activation.
    Plugariu CG; Wu SJ; Zhang W; Chaiken I
    Biochemistry; 2000 Dec; 39(48):14939-49. PubMed ID: 11101310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Characterization of a receptor for interleukin-5 on pulmonary eosinophils with eosinophilic pneumonia].
    Chihara J; Nakajima S
    Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Dec; 30 Suppl():70-6. PubMed ID: 1306241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomization of the receptor alpha chain recruitment epitope reveals a functional interleukin-5 with charge depletion in the CD loop.
    Wu SJ; Li J; Tsui P; Cook R; Zhang W; Hu Y; Canziani G; Chaiken I
    J Biol Chem; 1999 Jul; 274(29):20479-88. PubMed ID: 10400676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutated interleukin-5 monomers are biologically inactive.
    McKenzie AN; Ely B; Sanderson CJ
    Mol Immunol; 1991; 28(1-2):155-8. PubMed ID: 1901378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular cloning and expression of the human interleukin 5 receptor.
    Murata Y; Takaki S; Migita M; Kikuchi Y; Tominaga A; Takatsu K
    J Exp Med; 1992 Feb; 175(2):341-51. PubMed ID: 1732409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokine receptors on Ly-1 B cells. IL-5 and its receptor system.
    Takatsu K; Takaki S; Hitoshi Y; Mita S; Katoh S; Yamaguchi N; Tominaga A
    Ann N Y Acad Sci; 1992 May; 651():241-58. PubMed ID: 1376043
    [No Abstract]   [Full Text] [Related]  

  • 35. Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5.
    Zhang J; Kuvelkar R; Murgolo NJ; Taremi SS; Chou CC; Wang P; Billah MM; Egan RW
    Int Immunol; 1999 Dec; 11(12):1935-44. PubMed ID: 10590259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delineation of IL-5 domains predicted to engage the IL-5 receptor complex.
    Dickason RR; Huston MM; Huston DP
    J Immunol; 1996 Feb; 156(3):1030-7. PubMed ID: 8557976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling.
    Broughton SE; Dhagat U; Hercus TR; Nero TL; Grimbaldeston MA; Bonder CS; Lopez AF; Parker MW
    Immunol Rev; 2012 Nov; 250(1):277-302. PubMed ID: 23046136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coiled coil miniprotein randomization on phage leads to charge pattern mimicry of the receptor recognition determinant of interleukin 5.
    Li C; Plugariu CG; Bajgier J; White JR; Liefer KM; Wu SJ; Chaiken I
    J Mol Recognit; 2002; 15(1):33-43. PubMed ID: 11870920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A composite C/EBP binding site is essential for the activity of the promoter of the IL-3/IL-5/granulocyte-macrophage colony-stimulating factor receptor beta c gene.
    van Dijk TB; Baltus B; Raaijmakers JA; Lammers JW; Koenderman L; de Groot RP
    J Immunol; 1999 Sep; 163(5):2674-80. PubMed ID: 10453008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Asymmetric usage of antagonist charged residues drives interleukin-5 receptor recruitment but is insufficient for receptor activation.
    Ishino T; Pillalamarri U; Panarello D; Bhattacharya M; Urbina C; Horvat S; Sarkhel S; Jameson B; Chaiken I
    Biochemistry; 2006 Jan; 45(4):1106-15. PubMed ID: 16430207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.